Why did Glenmark Pharmaceuticals (GLENMARK) stock move recently?

On 7/29/2026, Glenmark Pharmaceuticals moved +3.5% — Glenmark's US subsidiary launched Sugammadex Injection (generic) single-dose vials in the US market, a product with ~$1.6B in annual sales, per the July 28 BSE press release. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Glenmark Pharmaceuticals (GLENMARK) overvalued or fairly valued?

MarketChacha shows Glenmark Pharmaceuticals's valuation in context — a forward P/E of about 23.3, a price-to-book of about 6.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Glenmark Pharmaceuticals's revenue?

Glenmark Pharmaceuticals reported revenue of ₹8,440 Cr for FY2026, with net profit of ₹-201 Cr, per official filings.

What is the share price of Glenmark Pharmaceuticals (GLENMARK)?

Glenmark Pharmaceuticals last traded at ₹2,276.00 (+1.1% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Glenmark Pharmaceuticals

GLENMARK · NSE · Pharma · India

Snapshot

TickerGLENMARK

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersMumbai, India

Websiteglenmarkpharma.com

Filings tracked2

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Who owns it

Promoters49.0%
Institutions27.7%
Public & other23.4%

115 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 4.7 points over the period — profitability is trending down.

Net margin trend2.3% → -2.4%

Margin has compressed by about 4.7 points over the period — profitability is trending down.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,263 Cr

Next fiscal year

Rev ₹18,712 Cr · EPS 97.67

Est. earnings growth +22.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹8,440 Cr

Net margin

-2.4%

Revenue CAGR (3y)

-13.4%

EPS (FY2026)

-7.12

Net profit (FY2026)

₹-201 Cr

Ask MarketChacha about GLENMARK

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
Glenmark's US subsidiary launched Sugammadex Injection (generic) single-dose vials in the US market, a product with ~$1.6B in annual sales, per the July 28 BSE press release.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹8,440 Cr	₹-201 Cr	-7.12	-2.4%
FY2025	₹13,322 Cr	₹1,047 Cr	—	7.9%
FY2024	₹11,813 Cr	₹-1,502 Cr	—	-12.7%
FY2023	₹12,990 Cr	₹297 Cr	—	2.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹2,435 Cr	₹736 Cr	26.07	30.2%
2026Q1	₹2,147 Cr	₹-74 Cr	-2.62	-3.4%
2025Q4	₹2,360 Cr	₹282 Cr	10.00	12.0%
2025Q3	₹6,047 Cr	₹610 Cr	—	10.1%
2025Q2	₹3,264 Cr	₹47 Cr	—	1.4%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Investor Presentation
Investor Presentation - Q1 FY 26-27
BSE7/31/2026
Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
BSE7/28/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.